We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · June 14, 2021

Pembrolizumab Alone or Combined With Chemotherapy vs Chemotherapy as First-Line Therapy for Advanced Urothelial Carcinoma

The Lancet Oncology

 

Additional Info

The Lancet Oncology
Pembrolizumab Alone or Combined With Chemotherapy Versus Chemotherapy as First-Line Therapy for Advanced Urothelial Carcinoma (KEYNOTE-361): A Randomised, Open-Label, Phase 3 Trial
Lancet Oncol 2021 May 26;[EPub Ahead of Print], T Powles, T Csőszi, M Özgüroğlu, N Matsubara, L Géczi, SY Cheng, Y Fradet, S Oudard, C Vulsteke, R Morales Barrera, A Fléchon, S Gunduz, Y Loriot, A Rodriguez-Vida, R Mamtani, EY Yu, K Nam, K Imai, B Homet Moreno, A Alva

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.